Zaptuzumab - CAS 2378046-35-4

Zaptuzumab (AD5-10) is a humanized monoclonal antibody targeting death receptor 5 (DR5) with high selective binding affinity. It specifically induces cancer cell death through caspase-mediated apoptosis and autophagic cell death (ACD) . Zaptuzumab can activate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) . Additionally, it induces reactive oxygen species (ROS) production and reduces glutathione (GSH) levels. In various xenograft mouse tumor models, Zaptuzumab has demonstrated significant tumor growth inhibition and favorable safety profiles.

Autophagy, JNK, ATG, Apoptosis, Caspase, Akt, TNF

Autophagy, Proteases/Proteasome, Apoptosis, Cytoskeletal Signaling, MAPK, PI3K/Akt/mTOR signaling

2378046-35-4

-20°C

Ice Packs

Inhibitory Antibodies